CLOVER HEALTH INVESTMENTS, CORP.CLOV
| Dec 31,
2020 | Dec 31,
2021 | Dec 31,
2022 |
|---|
| Net loss | -6,744,840 | -588 | -339 |
|---|
| Depreciation and amortization expense | - | 1 | 1 |
|---|
| Amortization of Debt Issuance Costs and Discounts | - | 14 | 0 |
|---|
| Stock-based compensation expense | - | 164 | 164 |
|---|
| Increase Decrease In Fair Value Adjustment Of Warrants | - | -66 | -1 |
|---|
| Accretion, net of amortization | - | 0 | -2 |
|---|
| Net realized losses on investment securities | - | - | -0 |
|---|
| Gain on extinguishment of note payable | - | - | 23 |
|---|
| Gain on investment | - | - | 9 |
|---|
| Premium deficiency reserve | - | 111 | -94 |
|---|
| Accrued retrospective premiums | - | -0 | 15 |
|---|
| Other receivables | - | 3 | 9 |
|---|
| Reinsurance recoverable | - | 0 | - |
|---|
| Surety bonds and deposits | - | 13 | 7 |
|---|
| Prepaid expenses | 299,666 | 2 | 3 |
|---|
| Other assets | - | 20 | 1 |
|---|
| Healthcare receivables | - | 9 | 23 |
|---|
| Non-Insurance receivable | - | - | 41 |
|---|
| Operating lease right-of-use assets | - | 4 | 2 |
|---|
| Unpaid claims | - | 37 | 3 |
|---|
| Accounts payable and accrued expenses | - | 5 | 8 |
|---|
| Accrued salaries and benefits | - | 11 | 9 |
|---|
| Deferred rent | - | -0 | - |
|---|
| Other liabilities | - | 1 | 2 |
|---|
| Performance year obligation | - | 37 | 37 |
|---|
| Non-Insurance payable | - | - | 110 |
|---|
| Operating lease liabilities | - | -4 | -3 |
|---|
| Net cash used in operating activities | -2,227,118 | -282 | -204 |
|---|
| Purchases of short-term investments, available-for-sale, and held-to-maturity securities | - | 876 | 369 |
|---|
| Proceeds From Sale Of Short-Term Investments And Available-For-Sale Securities | - | 127 | 13 |
|---|
| Proceeds from maturities of short-term investments, available-for-sale, and held-to-maturity securities | - | - | 472 |
|---|
| Acquisition of business, net of cash acquired | - | - | 16 |
|---|
| Purchases of property and equipment | - | 1 | 4 |
|---|
| Acquisition of Character Biosciences, Inc. Series A preferred shares | - | - | 0 |
|---|
| Net cash provided by (used in) investing activities | -828,000,000 | -435 | 95 |
|---|
| Payment of notes payable principal | 300,000 | 31 | - |
|---|
| Issuance of common stock, net of early exercise liability | - | 6 | 1 |
|---|
| Proceeds From Reverse Capitalization Net of Transaction Costs | - | 666 | - |
|---|
| Proceeds from Warrant Exercises | - | 0 | - |
|---|
| Proceeds from Issuance of Common Stock | 25,000 | 284 | - |
|---|
| Payment for the redemptions of public warrants | - | 0 | - |
|---|
| Treasury stock acquired | - | 0 | 6 |
|---|
| Net cash (used in) provided by financing activities | 858 | 925 | -5 |
|---|
| Net (decrease) increase in cash, cash equivalents, and restricted cash | - | 208 | -114 |
|---|
| Cash paid during the period for interest | - | 2 | - |
|---|
| Conversion of Stock, Amount Converted | - | 448 | - |
|---|
| Debt Conversion, Converted Instrument, Amount | - | 16 | - |
|---|
| Extinguishment of Debt, Amount | - | 127 | - |
|---|
| Activities from Seek Dissolution | - | - | 1 |
|---|
| Issuance of common stock related to warrants exercised | - | 98 | - |
|---|
| Acquisition of public and private warrants | - | 148 | - |
|---|
| Stock Issued | - | 81 | - |
|---|
| Lease Obligation Incurred | - | 1 | 1 |
|---|
| Transfer to Investments | - | - | 9 |
|---|
| Derecognition of noncontrolling interest | - | - | 4 |
|---|
| Conversion of Convertible Note to Preferred Stock | - | - | 0 |
|---|